Dzhelil Osmanov

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

Craig H. Moskowitz, Auayporn Nademanee, Tamás Masszi et al. · The Lancet · 2015 · 734 citations · Full text

Medicine, Immunology, Oncology +15

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Judith Trotman, Sally F. Barrington, David Belada et al. · The Lancet Oncology · 2018 · 159 citations · Full text

Medicine, Immunology, Oncology +13

Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial

Won Seog Kim, Christian Buske, Michinori Ogura et al. · The Lancet Haematology · 2017 · 75 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +8

A drug–drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies

Jan de Jong, Peter Hellemans, Severijn De Wilde et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2018 · 48 citations

Medicine, Pharmacology, Pharmacotherapy +16

Chromosomal characteristics of malignant lymphoma

E. W. Fleischman, E. L. Prigogina, G.W. Ilynskaya et al. · Human Genetics · 1989 · 38 citations

Life Sciences, Hematology, Oncology +14